The U.S. Food and Drug Administration (FDA) recently granted the pediatric disease designation for nipocalimab. Janssen is expecting that nipocalimab to contribute to its goal of achieving above-market growth.
In a statement, Johnson & Johnson’s Executive Vice President Jennifer Taubert said, “This acquisition broadens Janssen’s leadership in autoimmune diseases and provides us with a major catalyst for sustained growth. Autoantibody-driven diseases are often serious, and patients are underserved by current treatment options. ”
On the other hand, Momenta President and CEO Craig Wheeler said, “The agreement with J&J recognizes the value created by years of commitment and dedication to our mission by the many current and past Momenta employees. Programs such as nipocalimab have the potential to improve the lives of countless patients suffering from autoimmune and fetal-maternal diseases.”
Wheeler added that the transaction provides strong value for Momenta’s shareholders. He believes that Johnson & Johnson is a “strong fit for Momenta because both companies’ have a similar vision of pioneering therapies for complex diseases
